Occam Recruits Chief Commercial Officer at Geron
In September 2024, Occam Global recruited Jim Ziegler as Chief Commercial Officer of Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical oncology company.
In this role, Ziegler will spearhead the company’s global commercial strategy and operations and drive the growth of RYTELO™, Geron’s first marketed product.
Ziegler has over 25 years of commercial experience in the biopharmaceutical industry, spanning strategic and operational leadership roles in large and smaller organizations.
Ziegler joins Geron from Iovance Biotherapeutics (Nasdaq:IOVA), where he served as Executive Vice President of Commercial, with global responsibilities for the company’s novel autologous cell therapy program and led the U.S. commercial launch of Amtagvi™. Previously, he served in numerous commercial leadership roles at Gilead, Biogen, Amgen, and Pfizer.
Prior to the biopharmaceutical industry, Jim honorably served his country as an Armor Officer in the U.S. Army. Ziegler received a B.S. from the United States Military Academy at West Point and an M.B.A. from the University of Chicago.
Read more about Occam's work with Geron in our case study.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.